MicroPort CardioFlow Medtech Corporation informed the shareholders and potential investors of the company about the latest business advancement of the Group. The board of directors of the company announced that the transcatheter mitral valve replacement system (TMVR System) independently developed by the Group made progress with its clinical application and has been successfully used in the treatment of several patients with severe mitral regurgitation (MR), of which the first patient has recently completed one-year follow-up with positive results, while the three-month and one-month follow-up results of the other patients are also encouraging, all achieving significant MR reduction with no recurrence, no perivalvular leakage, no left ventricular outflow tract obstruction (LVOTO), and notable improvement of cardiac function-related indicators, all patients reported that the discomfort caused by MR had been significantly relieved. TMVR System is the world's first dry-tissue TMVR product with clinical application, and its multiple successful in-man applications and excellent follow-up results further validated the effectiveness and safety of the system, marking a new phase in its clinical application.

The TMVR System applied the dry tissue technology independently developed by the Group for the first time, which shows better biocompatibility and anti-calcification properties, and facilitates preoperative preparation, storage and transportation. The simplicity in its prosthetic valve design greatly reduces the operational difficulty and the LVOTO risk, bringing excellent hemodynamic performance and solving technical issues in transcatheter mitral valve replacement (TMVR) procedures such as prosthetic valve anchoring and fixation. The TMVR System adopted the transapical approach in all previous clinical applications, the operation of which is simple and physician-friendly.

In the several applications, the entry to withdrawal of the delivery system took only 15 minutes the shortest. MR is one of the most common life-threatening heart valve diseases. TMVR, as a widely discussed interventional treatment for structural heart diseases in recent years, still presents many technical issues in its clinical applications.

Based on deep understanding and exploration of clinical pain points, the company has accomplished several breakthroughs in key technologies and independently developed the TMVR System. The completion of multiple follow-ups of the TMVR System has once again demonstrated the Group's solid technical reserves and innovation capabilities in the field of structural heart diseases, further solidifying the foundation for the Group's comprehensive deployment in the field of structural heart diseases. The company will accelerate the multi-center clinical applications of the TMVR System, and support its research and development process with more detailed medical evidence, so as to launch the product to the market as soon as possible, and address the global unmet needs of TMVR therapy.